Eli Lilly touts some mixed PhIII results for cluster headaches as Amgen, Novartis prep a market-busting move in migraine
With Amgen and Novartis eagerly awaiting their PDUFA date for the leading CGRP migraine drug Aimovig later this week, Eli Lilly is stepping up with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
